Last reviewed · How we verify
NCT07081243
Symplicity China Study
trial testing Symplicity Spyral Renal Denervation System in Resistant Hypertension in 500 participants. Currently enrolling.
30 June 2028
Quick facts
| Lead sponsor | Medtronic Vascular |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 11 November 2025 |
| Primary completion | 30 June 2028 |
| Estimated completion | 30 December 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- Symplicity Spyral Renal Denervation System
Conditions studied
- Resistant Hypertension — all drugs for Resistant Hypertension →
Sponsor
Medtronic Vascular — full company profile →
Who can join
18 and older, any sex, with Resistant Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Symplicity China study will evaluate the real-world long-term safety, efficacy, and durability of the Symplicity Spyral system in a population of approximately 500 renal denervation treated subjects with up to 36 months of follow up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07081243
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Resistant Hypertension
Currently open trials in the same condition.
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
- NCT07207226 — Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension · NA · recruiting
- NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
- NCT05888233 — Allopurinol Improves Heart Function in African Americans With Resistant Hypertension · Phase 2 · recruiting
- NCT06450327 — Resistant Hypertension An Open, Complicated ("Cum Plicare") or Complex ("Cum Plexus") Syndrome? · recruiting
Other Medtronic Vascular trials
Trials by the same sponsor.
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
- NCT07013929 — Spyral InSight Study · NA · recruiting
- NCT06907147 — SPYRAL GEMINI Pilot Study · NA · recruiting
- NCT05198674 — SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN · NA · active not recruiting
- NCT04311086 — SPYRAL DYSTAL Renal Denervation Global Clinical Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07081243 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medtronic Vascular
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07081243.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing